ImmunityBio (IBRX) Gross Margin (2023 - 2026)

ImmunityBio (IBRX) has 4 years of Gross Margin data on file, last reported at 99.46% in Q1 2026.

• On a quarterly basis, Gross Margin fell 19.0% year-over-year to 99.46% in Q1 2026; TTM through Mar 2026 was 99.34%, a 48.0% decrease from a year earlier, with the FY2025 full-year figure at 99.34%, down 66.0% from the prior year.
• Gross Margin for Q1 2026 stood at 99.46%, roughly flat from 99.0% in the prior quarter.
• Over the last five years, Gross Margin for IBRX reached as high as 100.0% in Q2 2023 and fell as low as 99.0% in Q4 2025.
• Historically, Gross Margin has averaged 99.75% across 4 years, with a median of 100.0% in 2023.
• Across the five-year window, Gross Margin changed 0 bps in 2024 and sank 100 bps in 2025, its largest moves.
• Year by year, Gross Margin stood at 100.0% in 2023, then changed by 0 bps to 100.0% in 2024, then dropped by 1 bps to 99.0% in 2025, then climbed by 0 bps to 99.46% in 2026.
• Per Business Quant data, the three most recent Gross Margin figures were 99.46% in Q1 2026, 99.0% in Q4 2025, and 99.45% in Q3 2025.